In This Section      
 

Erin Michos, MD, MHS

Ciccarone Center Research

Published By

Erin Michos, MD, MHS

Erin Michos, MD, MHS
Michos, Erin, MD, MHS

Erin Michos, MD, MHS, is the Associate Director of Preventive Cardiology and an Associate Professor of Medicine. Dr Michos is also Associate Professor of Epidemiology and an Associate Faculty of the Welch Center for Prevention, Epidemiology, and Clinical Research.

View my Johns Hopkins Medicine profile for more information and to request an appointment

View my Google Scholar profile

Landmark Articles

Vitamin D for the prevention of stroke incidence and disability: Promising but too early for prime time.

By: Michos ED, Gottesman RF.

Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: Reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Heal

By: Michos ED, Sibley CT, Baer JT, Blaha MJ, Blumenthal RS.
Despite substantial risk reductions targeting low-density lipoprotein cholesterol with statins, there remains significant residual risk as evidenced by incident and recurrent CVD events among statin-treated patients. Observational studies have shown that low levels of high-density lipoprotein cholesterol (HDL-C) are associated with increased CVD risk. It remains unclear whether strategies aimed at increasing HDL-C in addition to background statin therapy will further reduce risk.

Evidence-based use of statins for primary prevention of cardiovascular disease.

By: Minder CM, Blaha MJ, Horne A, Michos ED, Kaul S, Blumenthal RS.
Current national guidelines recommend statins as part of a comprehensive primary prevention strategy for patients with elevated low-density lipoprotein cholesterol at increased risk for developing coronary heart disease within 10 years. However, we believe data provide compelling evidence to support the use of statins for primary prevention in patients with risk factors for developing coronary heart disease over the next decade.

25-Hydroxyvitamin D deficiency is associated with fatal stroke among whites but not blacks: The NHANES-III linked mortality files.

By: Michos ED, Reis JP, Post WS, Lutsey PL, Gottesman RF, Mosley TH, Sharrett AR, Melamed ML.

Deficient 25-hydroxyvitamin D (25[OH]D) levels are associated with cardiovascular disease (CVD) events and mortality. 25(OH)D deficiency and stroke are more prevalent in blacks. We examined whether low 25(OH)D contributes to the excess risk of fatal stroke in blacks compared with whites. Vitamin D deficiency was associated with an increased risk of stroke death in whites but not in blacks. Although blacks had a higher rate of fatal stroke compared with whites, the low 25(OH)D levels in blacks were unrelated to stroke incidence. Therefore 25(OH)D levels did not explain this excess risk.

Neighborhood health-promoting resources and obesity risk (the Multi-Ethnic Study of Atherosclerosis).

By: Auchincloss AH, Mujahid MS, Shen M, Michos ED, Whitt-Glover MC, Diez Roux AV.

Altering the residential environment so that healthier behaviors and lifestyles can be easily chosen may be a precondition for sustaining existing healthy behaviors and for adopting new healthy behaviors.

How accurate are 3 risk prediction models in US women?

By: Michos ED, Blumenthal RS.
We review the strengths and limitations of the Reynolds Risk Score and the Framingham risk estimates for myocardial infarction (MI) prediction and for major CVD event prediction.

Prediction of coronary artery calcium progression in individuals with low Framingham Risk Score: the Multi-Ethnic Study of Atherosclerosis.

By: Okwuosa TM, Greenland P, Burke GL, Eng J, Cushman M, Michos ED, Ning H, Lloyd-Jones DM.
In individuals at low predicted risk, according to Framingham Risk Scores, traditional risk factors predicted CAC progression in the short term with good discrimination and calibration. Prediction improved minimally when various novel markers were added to the model.

Making the case for selective use of statins in the primary prevention setting.

By: Minder CM, Blaha MJ, Tam LM, Munoz D, Michos ED, Kaul S, Blumenthal RS.
In this paper, we refute the incorrect view expressed by several members of the Archives editorial board in their “Less is More” column that lipid lowering is rarely indicated in the primary prevention setting.

Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis.

By: Sanchez DR, Diez Roux AV, Michos ED, Blumenthal RS, Schreiner PJ, Burke GL, Watson K.
The regular use of aspirin (?3 days/week) was examined in a cohort of 6,452 White, Black, Hispanic, and Chinese patients without cardiovascular disease in 2000 to 2002 and 5,181 patients from the same cohort in 2005 to 2007. Framingham risk scores were stratified into low (<6% risk of MI over next decade), increased (6% to 9.9%), and high (?10%) risk. In 2000 to 2002 prevalences of aspirin use were 18% and 27% for those at increased and high risk, respectively. In conclusion, regular aspirin use in adults at increased and high risk for CHD remains suboptimal. Important racial/ethnic disparities exist for unclear reasons.

Vitamin D in atherosclerosis, vascular disease, and endothelial function.

By: Brewer LC, Michos ED, Reis JP.
Vitamin D deficiency has been linked to an increased risk of hypertension, diabetes, congestive heart failure, peripheral arterial disease, MI, CVA, and related mortality, even after adjustment for traditional cardiovascular risk factors. Accumulating evidence from experimental, clinical, and epidemiological studies suggests that vitamin D may also be associated with several indices of vascular function, including the development and progression of atherosclerotic cardiovascular disease. These findings may provide at least a partial explanation for several recent epidemiologic studies implicating low vitamin D status in the pathogenesis of cardiovascular disease. However, large-scale, well-conducted, placebo controlled clinical trials testing the efficacy of vitamin D supplementation in delaying, slowing, or reversing the atherosclerotic disease process have not yet been conducted. Until the results of these studies are available, we believe it is premature to recommend vitamin D as a therapeutic option in atherosclerosis.